170 related articles for article (PubMed ID: 28042310)
1. Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.
Gerullis H; Wawroschek F; Köhne CH; Ecke TH
Ther Adv Urol; 2017 Jan; 9(1):28-35. PubMed ID: 28042310
[TBL] [Abstract][Full Text] [Related]
2. Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review.
Gerullis H; Ecke T; Eimer C; Wishahi M; Otto T
Anticancer Drugs; 2011 Jan; 22(1):9-17. PubMed ID: 20948429
[TBL] [Abstract][Full Text] [Related]
3. Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series.
Bamias A; Hegele A; Medioni J; Castellano D; Doni L; Passalacqua R; Zagouri F; Tzannis K; Hussain S; Ullen A
Crit Rev Oncol Hematol; 2019 Aug; 140():80-87. PubMed ID: 31133463
[TBL] [Abstract][Full Text] [Related]
4. From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples.
Facchini G; Della Pepa C; Cavaliere C; Cecere SC; Di Napoli M; D'Aniello C; Crispo A; Iovane G; Maiolino P; Tramontano T; Piscitelli R; Pisconti S; Montella M; Berretta M; Sorrentino D; Perdonà S; Pignata S
Front Pharmacol; 2016; 7():110. PubMed ID: 27199753
[TBL] [Abstract][Full Text] [Related]
5. Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance.
Gerullis H; Ecke TH; Janusch B; Arndt C; Heidari M; Oniani J; Otto T
Anticancer Drugs; 2011 Oct; 22(9):940-3. PubMed ID: 21642839
[TBL] [Abstract][Full Text] [Related]
6. Safety of Vinflunine in Patients with Advanced Urothelial Carcinoma Refractory to Platinum-based Chemotherapy: A Prospective Pilot Study.
Abdel-Malek R; Shohdy KS; Abbas N; Ismail M; Hamada E; Abdel-Kader Y
Curr Drug Saf; 2019; 14(1):31-36. PubMed ID: 30277164
[TBL] [Abstract][Full Text] [Related]
7. Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience.
Retz M; de Geeter P; Goebell PJ; Matz U; de Schultz W; Hegele A
BMC Cancer; 2015 Jun; 15():455. PubMed ID: 26040470
[TBL] [Abstract][Full Text] [Related]
8. Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report.
Bordi P; Tiseo M; Baldari G; Buti S
BMC Cancer; 2016 Aug; 16():626. PubMed ID: 27519420
[TBL] [Abstract][Full Text] [Related]
9. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).
Passalacqua R; Lazzarelli S; Donini M; Montironi R; Tambaro R; De Giorgi U; Pignata S; Palumbo R; Ceresoli GL; Del Conte G; Tonini G; Morelli F; Nolè F; Panni S; Rondini E; Guida A; Zucali PA; Doni L; Iezzi E; Caminiti C
BMC Cancer; 2017 Jul; 17(1):493. PubMed ID: 28724419
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy - results of an exploratory phase I study.
Pappot H; von der Maase H; Ullén A; Agerbæk M;
Invest New Drugs; 2018 Aug; 36(4):615-618. PubMed ID: 29081023
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours.
Delord JP; Tourani JM; Lefresne F; Pétain A; Pouget JC; Ravaud A
Cancer Chemother Pharmacol; 2013 Mar; 71(3):647-56. PubMed ID: 23299791
[TBL] [Abstract][Full Text] [Related]
12. Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy.
Houédé N; Locker G; Lucas C; Parra HS; Basso U; Spaeth D; Tambaro R; Basterretxea L; Morelli F; Theodore C; Lusuardi L; Lainez N; Guillot A; Tonini G; Bielle J; Del Muro XG
BMC Cancer; 2016 Sep; 16(1):752. PubMed ID: 27664126
[TBL] [Abstract][Full Text] [Related]
13. Vinflunine in Metastatic Urothelial Carcinoma of the Bladder in Progression after a Platinum-Containing Regimen.
De Luca R; Profita G; Vella M; Cicero G
Oncology; 2019; 97(6):341-347. PubMed ID: 31461721
[TBL] [Abstract][Full Text] [Related]
14. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW
J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042
[No Abstract] [Full Text] [Related]
15. Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series.
Palumbo R; Licata L; Sottotetti F; Tagliaferri B; Pozzi E; Teragni C; Quaquarini E; Bernardo A
Oncol Res Treat; 2018; 41(1-2):8-13. PubMed ID: 29402855
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.
Gerullis H; Eimer C; Ecke TH; Georgas E; Arndt C; Otto T
Anticancer Drugs; 2013 Apr; 24(4):422-5. PubMed ID: 23407060
[TBL] [Abstract][Full Text] [Related]
17. [Care of advanced or metastatic bladder cancer in second line: A specific place for vinflunine].
Houédé N; Milano G
Bull Cancer; 2019 May; 106(5):431-435. PubMed ID: 30981463
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.
Krzakowski M; Ramlau R; Jassem J; Szczesna A; Zatloukal P; Von Pawel J; Sun X; Bennouna J; Santoro A; Biesma B; Delgado FM; Salhi Y; Vaissiere N; Hansen O; Tan EH; Quoix E; Garrido P; Douillard JY
J Clin Oncol; 2010 May; 28(13):2167-73. PubMed ID: 20351334
[TBL] [Abstract][Full Text] [Related]
20. Which place for avelumab in the management of urothelial carcinoma?
Larroquette M; Gross-Goupil M; Daste A; Robert G; Ravaud A; Domblides C
Expert Opin Biol Ther; 2019 Sep; 19(9):863-870. PubMed ID: 31286802
[No Abstract] [Full Text] [Related]
[Next] [New Search]
